What they were paid
Stoke Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $60,000 | — | $223,338 | $0 | $283,338 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Stoke Therapeutics, Inc. DEF 14A filed April 22, 2026, accession 0001193125-26-170362, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Stoke Therapeutics pays directors a $40,000 cash retainer and $224,000 in Options.
Committees
FY2025 · as the proxy prints themAudit · Compensation · Research and Development
The rest of the Stoke Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Adrian R. Krainer, Ph.D | Independent Director | $268,338 |
| Arthur A. Levin, Ph.D | Independent Director | $281,249 |
| Arthur O. Tzianabos, Ph.D | Independent Director | $778,778 |
| Edward M. Kaye, M.D | Independent Director | — |
| Garry E. Menzel, Ph.D | Independent Director | $280,838 |
| Ian F. Smith | Chair of the Board | $0 |
| Jennifer C. Burstein, CPA | Independent Director | $283,338 |
| Seth L. Harrison, M.D | Independent Director | $270,838 |
The full Stoke Therapeutics compensation record
free company briefThis page is one director within Stoke Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat